ISB News

Metabolic Changes in Plasma and Immune Cells Associated with COVID-19 Severity, May Predict Patient Survival

Drs. Jim Heath, Yapeng Su and Jihoon Lee

A research team including, from left to right, ISB’s Drs. Jim Heath and Yapeng Su and Fred Hutch’s Dr. Jihoon Lee, have uncovered underlying metabolic changes that are associated with COVID-19 severity, and may predict survival.

Researchers from Institute for Systems Biology (ISB), Fred Hutchinson Cancer Research Center and other organizations have uncovered underlying metabolic changes that regulate how immune cells react to COVID-19. The findings were published in the journal Nature Biotechnology.

Patients have differing immune responses that lead to COVID-19 severity outcomes ranging from asymptomatic SARS-CoV-2 infection to death. After examining the blood samples from nearly 200 COVID-19 patients, researchers have uncovered underlying metabolic changes that regulate how immune cells react to the disease. These changes are associated with disease severity and could be used to predict patient survival. 

“We know that there are a range of immune responses to COVID-19, and the biological processes underlying those responses are not well understood,” said co-first author Jihoon Lee, a graduate student at Fred Hutchinson Cancer Research Center. “We analyzed thousands of biological markers linked to metabolic pathways that underlie the immune system and found some clues as to what immune-metabolic changes may be pivotal in severe disease. Our hope is that these observations of immune function will help others piece together the body’s response to COVID-19. The deeper understanding gained here may eventually lead to better therapies that can more precisely target the most problematic immune or metabolic changes.” 

The researchers collected 374 blood samples – two draws per patient during the first week after being diagnosed with SARS-CoV-2 infection – and analyzed their plasma and single immune cells. The analysis included 1,387 genes involved in metabolic pathways and 1,050 plasma metabolites.

‘Significant insights for developing more effective treatments’

In plasma samples, the team found that increased COVID-19 severity is associated with metabolite alterations, suggesting increased immune-related activity. Furthermore, through single-cell sequencing, researchers found that each major immune cell type has a distinct metabolic signature. 

“We have found metabolic reprogramming that is highly specific to individual immune cell classes (e.g. ‘killer’ CD8+ T cells, ‘helper’ CD4+ T cells, antibody-secreting B cells, etc.) and even cell subtypes, and the complex metabolic reprogramming of the immune system is associated with the plasma global metabolome and is predictive of disease severity and even patient death,” said co-first and co-corresponding author Dr. Yapeng Su, a research scientist at ISB. “Such deep and clinically relevant insights on sophisticated metabolic reprogramming within our heterogeneous immune systems are otherwise impossible to gain without advanced single-cell multi-omic analysis.”

“This work provides significant insights for developing more effective treatments against COVID-19. It also represents a major technological hurdle,” said Dr. Jim Heath, president and professor of ISB and co-corresponding author on the paper. “Many of the data sets that are collected from these patients tend to measure very different aspects of the disease, and are analyzed in isolation. Of course, one would like these different views to contribute to an overall picture of the patient. The approach described here allows for the sum of the different data sets to be much greater than the parts, and provides for a much richer interpretation of the disease.” 

The research was conducted by scientists from ISB, Fred Hutchinson Cancer Research Center, Stanford University, Swedish Medical Center St. John’s Cancer Institute at Saint John’s Health Center, the University of Washington, the Howard Hughes Medical Institute.

Funding for this project comes from Merck and the Biomedical Advanced Research and Development Authority (BARDA), the Wilke Family Foundation, the MJ Murdock Charitable Trust, the Swedish Medical Center Foundation, the Parker Institute for Cancer Immunotherapy, Gilead, Amazon Web Services, and the National Institutes of Health.

Recent Articles

  • Gut Microbiome Composition Predictive of Patient Response to Statins

    New ISB research shows that different patient responses to statins can be explained by the variation in the human microbiome. The findings were published in the journal Med, and suggest that microbiome monitoring could be used to help optimize personalized statin treatments.

  • Risk Factors for Severe COVID-19 in Hospitalized Adults Differ by Age

    A just-published study provides new information about which hospitalized COVID-19 patients are most likely to need mechanical ventilation or to die. The ISB-led work shows that vital signs and lab results at the time of hospital admission are the most accurate predictors of disease severity, more so than comorbidities and demographics.

  • Spotlight on ISB Education graphic

    2021-22 School Year ISB Education Highlights

    From planning, creating and executing workshops for educators to forging new relationships to elevate students, the ISB Education team has been in high gear. Each month throughout the 2021-2022 academic year, we will highlight some of the top projects the team is working on.